Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1651 to 1660 of 1856 total matches.
Desogestrel - A New Progestin for Oral Contraception
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993 (Issue 902)
available in a 28-day regimen at slightly different cost.
THE MEDICAL LETTER (ISSN 1523-2859) is published ...
Desogen (Organon) and Ortho-Cept (Ortho), two oral contraceptives each containing a low dose (30 mcg) of the estrogen ethinyl estradiol plus 150 mcg of the progestin desogestrel, were recently approved by the US Food and Drug Administration for marketing in the USA. They are the first US oral contraceptives to contain desogestrel, which is widely used in oral contraceptive combination products in other countries. Desogestrel is one of three new progestins (norgestimate and gestodene are the others) considered less androgenic than previously available progestins (L Speroff et al, Obstet...
Two New Retinoids for Psoriasis
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997 (Issue 1013)
, which has a half-life of 120 days, acitretin (a
si tre’ tin) is not stored in adipose tissue ...
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis.
Drug Interactions with St. John's Wort
The Medical Letter on Drugs and Therapeutics • Jun 26, 2000 (Issue 1081)
of digoxin (Lanoxin, and others) in healthy volunteers who took St. John’s wort for 10 days (A Johne
et al ...
Even though its effectiveness has not been established, many patients take St. John's Wort (Hypericum perforatum), an over-the-counter herbal extract, to treat symptoms of depression, often without the knowledge of their physicians. Recent reports indicate that St. John's wort interacts adversely with a number of drugs.
Gemtuzumab for Relapsed Acute Myeloid Leukemia
The Medical Letter on Drugs and Therapeutics • Jul 24, 2000 (Issue 1083)
doses 14 days apart. The mean
half-life of calicheamicin after the second dose is about 60 hours ...
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able to tolerate cytotoxic chemotherapy
A New Long-acting Methylphenidate (Concerta)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2000 (Issue 1086)
Amphetamine mixture
Adderall (Shire-Richwood) 5 mg b.i.d., 5 hours apart 25.77
* Cost for 30 days’ treatment ...
Methylphenidate (Ritalin, and others) is now available in a new extended-release formulation (Concerta--Alza) for treatment of attention deficit/hyperactivity disorder (ADHD).
Topical Tacrolimus For Treatment of Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 16, 2001 (Issue 1102)
apparent within seven days. A randomized, double-blind trial in 351 children comparing the vehicle alone ...
Tacrolimus ointment (Protopic) has been approved by the FDA in 0.03% and 0.1% formulations for treatment of atopic dermatitis. Tacrolimus is used systemically (Prograf) to prevent rejection of organ transplants.
Screening For Lung Cancer
The Medical Letter on Drugs and Therapeutics • Jul 23, 2001 (Issue 1109)
smokers more than 60
years old with a history of at least 10 pack-years (eg, one pack a day for 10 years ...
Most patients with lung cancer present with advanced disease, and fewer than 20% live for five years after diagnosis. Earlier detection of lung cancer, when it is potentially resectable, might improve survival. Recent studies have led some radiology centers to promote spiral computed tomography (CT), which involves much less exposure to radiation than standard CT, as a screening tool for lung cancer.
Cardiovascular Safety of Cox-2 Inhibitors
The Medical Letter on Drugs and Therapeutics • Nov 12, 2001 (Issue 1118)
, which has an antiplatelet effect for the life
of the platelet, an average of about 7 days. Selective ...
Related Articles Since Publication
Increasing use of rofecoxib (Vioxx) and celecoxib (Celebrex), both selective inhibitors of cyclooxygenase-2 (COX-2), for treatment of arthristis has been accompanied by concerns that they may increase risk of thrombotic cardiovascular events.
Neotame - a new artificial sweetener
The Medical Letter on Drugs and Therapeutics • Aug 19, 2002 (Issue 1137)
of 18 mg/day. One tabletop packet would contain about 0.9 mg of neotame. Because of its ability ...
Neotame (Neotame - NutraSweet Co.), an analog of aspartame (NutraSweet, and others), has been approved by the FDA for use as a nonnutritive sweetener and "flavor enhancer" in foods and beverages. Other non-caloric sweeteners available in the US include saccharin (Sweet'N Low, and others), acesulfame potassium (Sunette - Medical Letter, 1988; 30:116) and sucralose (Splenda - Medical Letter, 1998; 40:67). Neotame was approved for use in Australia and New Zealand in 2001.
Rapid Tests for HIV Infection
The Medical Letter on Drugs and Therapeutics • Jul 07, 2003 (Issue 1160)
-day results and counseling has
become a public health priority (MMWR Morb Mortal Wkly Rep 2003; 52 ...
Testing for HIV infection in the US typically has been a two-step process that requires patients to return for results. This review describes two rapid tests currently FDA-approved, OraQuick and Reveal. It includes a table with the cost and characteristics of each test (result time, device type, equipment needed, etc.).